• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变型 p53 作为癌细胞的守护者。

Mutant p53 as a guardian of the cancer cell.

机构信息

Laboratorio Nazionale CIB (LNCIB), AREA Science Park, Trieste, Italy.

Dipartimento di Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy.

出版信息

Cell Death Differ. 2019 Jan;26(2):199-212. doi: 10.1038/s41418-018-0246-9. Epub 2018 Dec 11.

DOI:10.1038/s41418-018-0246-9
PMID:30538286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6329812/
Abstract

Forty years of research have established that the p53 tumor suppressor provides a major barrier to neoplastic transformation and tumor progression by its unique ability to act as an extremely sensitive collector of stress inputs, and to coordinate a complex framework of diverse effector pathways and processes that protect cellular homeostasis and genome stability. Missense mutations in the TP53 gene are extremely widespread in human cancers and give rise to mutant p53 proteins that lose tumor suppressive activities, and some of which exert trans-dominant repression over the wild-type counterpart. Cancer cells acquire selective advantages by retaining mutant forms of the protein, which radically subvert the nature of the p53 pathway by promoting invasion, metastasis and chemoresistance. In this review, we consider available evidence suggesting that mutant p53 proteins can favor cancer cell survival and tumor progression by acting as homeostatic factors that sense and protect cancer cells from transformation-related stress stimuli, including DNA lesions, oxidative and proteotoxic stress, metabolic inbalance, interaction with the tumor microenvironment, and the immune system. These activities of mutant p53 may explain cancer cell addiction to this particular oncogene, and their study may disclose tumor vulnerabilities and synthetic lethalities that could be exploited for hitting tumors bearing missense TP53 mutations.

摘要

四十年的研究已经确立,p53 肿瘤抑制因子通过其作为压力输入的极其敏感的收集器的独特能力,以及协调保护细胞内稳态和基因组稳定性的多种效应途径和过程的复杂框架,为肿瘤的发生和肿瘤的进展提供了主要的障碍。TP53 基因中的错义突变在人类癌症中极其普遍,并产生失去肿瘤抑制活性的突变 p53 蛋白,其中一些对野生型蛋白具有转录显性抑制作用。癌细胞通过保留突变形式的蛋白获得选择性优势,通过促进侵袭、转移和化疗耐药性,从根本上颠覆了 p53 通路的性质。在这篇综述中,我们考虑了现有的证据,这些证据表明,突变型 p53 蛋白可以通过充当感应和保护癌细胞免受与转化相关的应激刺激的稳态因子,包括 DNA 损伤、氧化和蛋白毒性应激、代谢失衡、与肿瘤微环境的相互作用以及免疫系统,从而有利于癌细胞的存活和肿瘤的进展。这些突变型 p53 的活性可以解释癌细胞对这种特定致癌基因的依赖性,它们的研究可能会揭示肿瘤的脆弱性和合成致死性,这些脆弱性和合成致死性可以被利用来攻击携带错义 TP53 突变的肿瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/dd64a5871d35/41418_2018_246_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/d9cb8deabe96/41418_2018_246_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/3ac552b8244b/41418_2018_246_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/1d5902e7b015/41418_2018_246_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/dd64a5871d35/41418_2018_246_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/d9cb8deabe96/41418_2018_246_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/3ac552b8244b/41418_2018_246_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/1d5902e7b015/41418_2018_246_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f35e/6329812/dd64a5871d35/41418_2018_246_Fig4_HTML.jpg

相似文献

1
Mutant p53 as a guardian of the cancer cell.突变型 p53 作为癌细胞的守护者。
Cell Death Differ. 2019 Jan;26(2):199-212. doi: 10.1038/s41418-018-0246-9. Epub 2018 Dec 11.
2
How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.突变如何塑造 p53 与基因组的相互作用,从而促进肿瘤发生和耐药性。
Drug Resist Updat. 2018 May;38:27-43. doi: 10.1016/j.drup.2018.05.001. Epub 2018 May 9.
3
Mutant p53 improves cancer cells' resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6.突变型 p53 通过维持未折叠蛋白反应调节剂 ATF6 的激活来提高癌细胞对内质网应激的抵抗力。
Oncogene. 2019 Aug;38(34):6184-6195. doi: 10.1038/s41388-019-0878-3. Epub 2019 Jul 16.
4
New therapeutic strategies to treat human cancers expressing mutant p53 proteins.治疗表达突变型 p53 蛋白的人类癌症的新治疗策略。
J Exp Clin Cancer Res. 2018 Feb 15;37(1):30. doi: 10.1186/s13046-018-0705-7.
5
p53 mutations in cancer.癌症中的 p53 突变。
Nat Cell Biol. 2013 Jan;15(1):2-8. doi: 10.1038/ncb2641.
6
The oncogenic roles of p53 mutants in mouse models.p53突变体在小鼠模型中的致癌作用。
Curr Opin Genet Dev. 2007 Feb;17(1):66-70. doi: 10.1016/j.gde.2006.12.003. Epub 2007 Jan 8.
7
The p53 tumor suppressor gene and gene product.p53肿瘤抑制基因及其基因产物。
Princess Takamatsu Symp. 1989;20:221-30.
8
Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe.突变型P53在肿瘤微环境形成与进展中的作用:助力还是阻碍。
Life Sci. 2023 Feb 15;315:121361. doi: 10.1016/j.lfs.2022.121361. Epub 2023 Jan 4.
9
Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.获得非整倍体导致突变型 p53 相关获得性功能表型。
Nat Commun. 2021 Aug 31;12(1):5184. doi: 10.1038/s41467-021-25359-z.
10
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.p53功能获得性癌症突变体通过使ATM失活诱导基因不稳定。
Nat Cell Biol. 2007 May;9(5):573-80. doi: 10.1038/ncb1571. Epub 2007 Apr 8.

引用本文的文献

1
Lead bioaccumulation in human breast cancer tissue is associated with DNA instability and cell death resistance.人体乳腺癌组织中的铅生物蓄积与DNA不稳定性和细胞抗死亡能力有关。
Cell Death Discov. 2025 Aug 15;11(1):383. doi: 10.1038/s41420-025-02676-6.
2
The Role of Nuclear Phosphoinositides in the p53-MDM2 Nexus.核磷酸肌醇在p53-MDM2关系中的作用。
Cells. 2025 Jul 22;14(15):1126. doi: 10.3390/cells14151126.
3
Systematic analysis of doxorubicin-induced myocardial injury mechanisms using network toxicology and molecular docking strategy.

本文引用的文献

1
Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells.砷靶向 Pin1,并与维甲酸协同抑制致癌途径和肿瘤起始细胞。
Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
2
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.功能获得性(GOF)突变型p53作为可操作的治疗靶点。
Cancers (Basel). 2018 Jun 7;10(6):188. doi: 10.3390/cancers10060188.
3
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.突变型p53调节NRF2依赖的抗氧化反应以支持癌细胞存活。
使用网络毒理学和分子对接策略对阿霉素诱导的心肌损伤机制进行系统分析。
Medicine (Baltimore). 2025 Aug 8;104(32):e43844. doi: 10.1097/MD.0000000000043844.
4
The urokinase receptor/uPAR is a major effector of p53 gain-of-function mutations in gemcitabine-treated pancreatic ductal adenocarcinoma.尿激酶受体/uPAR是吉西他滨治疗的胰腺导管腺癌中p53功能获得性突变的主要效应分子。
J Biol Chem. 2025 Aug 7;301(9):110561. doi: 10.1016/j.jbc.2025.110561.
5
Regulation of the MDM2-p53 Nexus by a Nuclear Phosphoinositide and Small Heat Shock Protein Complex.一种核磷酸肌醇与小分子热休克蛋白复合物对MDM2-p53关系的调控
J Biol Chem. 2025 Jul 26:110527. doi: 10.1016/j.jbc.2025.110527.
6
Knockdown of the snoRNA-Jouvence Blocks the Proliferation and Leads to the Death of Human Primary Glioblastoma Cells.小核仁RNA-Jouvence的敲低可阻断人原发性胶质母细胞瘤细胞的增殖并导致其死亡。
Noncoding RNA. 2025 Jul 18;11(4):54. doi: 10.3390/ncrna11040054.
7
The key target and role of betel nut in oral squamous cell carcinoma.槟榔在口腔鳞状细胞癌中的关键靶点及作用
BMC Oral Health. 2025 Jul 19;25(1):1212. doi: 10.1186/s12903-025-06558-2.
8
Dual-layer spectral detector CT: a non-invasive tool for simultaneously predicting Ki-67 proliferation status and p53 mutations in pancreatic ductal adenocarcinoma.双层光谱探测器CT:一种用于同时预测胰腺导管腺癌中Ki-67增殖状态和p53突变的非侵入性工具。
Abdom Radiol (NY). 2025 Jul 14. doi: 10.1007/s00261-025-05115-3.
9
missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer.错义特异性转录可塑性驱动胰腺癌对细胞周期抑制剂的抗性。
Sci Adv. 2025 Jul 4;11(27):eadu2339. doi: 10.1126/sciadv.adu2339.
10
Interplay between tumor cells and immune cells of the colorectal cancer tumor microenvironment: Wnt/β-catenin pathway.结直肠癌肿瘤微环境中肿瘤细胞与免疫细胞之间的相互作用:Wnt/β-连环蛋白信号通路
Front Immunol. 2025 Jun 18;16:1587950. doi: 10.3389/fimmu.2025.1587950. eCollection 2025.
Oncotarget. 2018 Apr 17;9(29):20508-20523. doi: 10.18632/oncotarget.24974.
4
The stiff RhoAd from mevalonate to mutant p53.从甲羟戊酸到突变型p53的僵硬RhoAd。 (注:“RhoAd”可能是特定专业术语,具体准确含义需结合更多背景信息确定,这里按字面翻译)
Cell Death Differ. 2018 Mar;25(4):645-647. doi: 10.1038/s41418-018-0091-x. Epub 2018 Mar 6.
5
Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246.突变型p53癌症通过外泌体miR-1246将巨噬细胞重编程为肿瘤支持性巨噬细胞。
Nat Commun. 2018 Feb 22;9(1):771. doi: 10.1038/s41467-018-03224-w.
6
Mutant p53 controls tumor metabolism and metastasis by regulating PGC-1α.突变型 p53 通过调控 PGC-1α 来控制肿瘤代谢和转移。
Genes Dev. 2018 Feb 1;32(3-4):230-243. doi: 10.1101/gad.309062.117. Epub 2018 Feb 20.
7
Synergistic and additive effect of retinoic acid in circumventing resistance to p53 restoration.维甲酸在规避对 p53 恢复的耐药性方面的协同和累加效应。
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2198-2203. doi: 10.1073/pnas.1719001115. Epub 2018 Feb 13.
8
Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis.机械线索通过甲羟戊酸-RhoA 轴控制突变型 p53 的稳定性。
Nat Cell Biol. 2018 Jan;20(1):28-35. doi: 10.1038/s41556-017-0009-8. Epub 2017 Dec 18.
9
Targeting mutant p53 for efficient cancer therapy.针对突变型 p53 进行有效的癌症治疗。
Nat Rev Cancer. 2018 Feb;18(2):89-102. doi: 10.1038/nrc.2017.109. Epub 2017 Dec 15.
10
Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy.精准打击癌症的代谢弱点
Trends Cell Biol. 2018 Mar;28(3):201-212. doi: 10.1016/j.tcb.2017.11.006. Epub 2017 Dec 8.